Johnson & Johnson Strengthens Neuroscience Leadership With Acquisition of Intra-Cellular Therapies, Inc.
January 14, 2025
January 14, 2025
NEW BRUNSWICK, New Jersey, Jan. 14 -- Johnson and Johnson issued the following news release:
* * *
Acquisition includes CAPLYTA (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults
sNDA submitted to U.S. FDA for CAPLYTA as adjunctive treatment for major depressive disorder; if approved, CAPLYTA has potential to become a stan . . .
* * *
Acquisition includes CAPLYTA (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults
sNDA submitted to U.S. FDA for CAPLYTA as adjunctive treatment for major depressive disorder; if approved, CAPLYTA has potential to become a stan . . .